Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
January 06, 2025 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
November 13, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 22, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
October 01, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 13, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 09, 2024 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 08, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
June 18, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 28, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update